Skip to main content
SpringerLink
Log in

IMRT, Hypofractionated Radiotherapy and Stereotactic Radiotherapy: Technique, Indications, and Results

  • Chapter
  • First Online:
Book cover Management of Prostate Cancer

  • 1305 Accesses

Abstract

The major technological advance in external beam radiotherapy in the 1990s was the introduction of conformal radiotherapy. For the first time, the high-dose volume was not constrained to be cuboid in shape, because the radiotherapy beam collimators were multi-leaf (instead of single leaf), the radiotherapy beam could be irregular in shape and did not have to be rectangular or square. The high dose volume could thus ‘conform’ more closely to the shape of the tumour, by tailoring the shape of the beam using multileaf collimators (MLCs); when introduced, this held the promise of reducing the total volume of tissue irradiated, and the randomised trial carried out by the Royal Marsden Hospital confirmed that this was, indeed the case [14]. However, as well as reducing treatment toxicity, conformal radiotherapy also permitted the alternative strategy of dose escalation, which was successfully deployed in a number of randomised trials and is now regarded as standard practice. The current European Association of Urology guidelines recommend a dose of 76–78 Gy in combination with ADT for intermediate-risk and high-risk disease, when given in ‘standard’ fraction sizes of 1.8–2 Gy per fraction [42].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Supplementary appendix describing the CHHIP radiotherapy planning protocol in detail is available at www.thelancet.com.

References

  1. Adams EJ, Convery DJ, Cosgrove VP, et al. Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement. Radiother Oncol. 2004;70:1–10. doi:10.1016/j.radonc.2003.09.004.

    Article  PubMed  Google Scholar 

  2. Al-Mamgani A, Heemsbergen WD, Peeters STH, Lebesque JV. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:685–91. doi:10.1016/j.ijrobp.2008.04.063.

    Article  PubMed  Google Scholar 

  3. Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17:464–74. doi:10.1016/S1470-2045(15)00567-7.

    Article  PubMed  Google Scholar 

  4. Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol. 2015;16:274–83. doi:10.1016/S1470-2045(14)70482-6.

    Article  PubMed  Google Scholar 

  5. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78:11–8. doi:10.1016/j.ijrobp.2009.07.1691.

    Article  PubMed  Google Scholar 

  6. Asbell SO, Krall JM, Pilepich MV, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77–06. Int J Radiat Oncol Biol Phys. 1988;15:1307–16.

    Article  CAS  PubMed  Google Scholar 

  7. Bauman G, Rumble RB, Chen J, et al. Intensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol (R Coll Radiol). 2012;24:461–73. doi:10.1016/j.clon.2012.05.002.

    Article  CAS  Google Scholar 

  8. Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80:1056–63. doi:10.1016/j.ijrobp.2010.03.049.

    Article  PubMed  Google Scholar 

  9. Bruner DW, Hunt D, Michalski JM, et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer. 2015;121:2422–30. doi:10.1002/cncr.29362.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Cooperberg MR. Expanding utilization of intensity-modulated radiotherapy for prostate cancer: soaring costs, dubious benefits: comment on “Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy”. JAMA Intern Med. 2013;173:1143–4. doi:10.1001/jamainternmed.2013.6755.

    Article  PubMed  Google Scholar 

  11. Dasu A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol. 2012;51:963–74. doi:10.3109/0284186X.2012.719635.

    Article  PubMed  Google Scholar 

  12. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13:43–54. doi:10.1016/S1470-2045(11)70293-5.

    Article  PubMed  Google Scholar 

  13. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15:464–73. doi:10.1016/S1470-2045(14)70040-3.

    Article  PubMed  Google Scholar 

  14. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 1999;353:267–72. doi:10.1016/S0140-6736(98)05180-0.

    Article  CAS  PubMed  Google Scholar 

  15. Decaestecker K, De Meerleer G, Ameye F, et al. Surveillance or metastasis-directed therapy for OligoMetastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14:671. doi:10.1186/1471-2407-14-671.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ezzell GA, Galvin JM, Low D, et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT subcommittee of the AAPM radiation therapy committee. Med Phys. 2003;30:2089–115. doi:10.1118/1.1591194.

    Article  PubMed  Google Scholar 

  17. Fowler JF, Toma-Dasu I, Dasu A. Is the α/β ratio for prostate tumours really low and does it vary with the level of risk at diagnosis? Anticancer Res. 2013;33:1009–11.

    PubMed  Google Scholar 

  18. Ghilezan M, Yan D, Liang J, et al. Online image-guided intensity-modulated radiotherapy for prostate cancer: how much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery. Int J Radiat Oncol Biol Phys. 2004;60:1602–10. doi:10.1016/j.ijrobp.2004.07.709.

    Article  PubMed  Google Scholar 

  19. Ghilezan MJ, Jaffray DA, Siewerdsen JH, et al. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005;62:406–17. doi:10.1016/j.ijrobp.2003.10.017.

    Article  PubMed  Google Scholar 

  20. Goldin GH, Sheets NC, Meyer A-M, et al. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. JAMA Intern Med. 2013;173:1136–43. doi:10.1001/jamainternmed.2013.1020.

    Article  PubMed  Google Scholar 

  21. Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013;119:1729–35. doi:10.1002/cncr.27956.

    Article  PubMed  Google Scholar 

  22. Harris V, South C, Cruickshank C, Dearnaley D. 1299 poster a national phase III trial of pelvic lymph node (LN) IMRT in prostate cancer (pivotal): a comparison of LN outlining methods. Radiother Oncol. 2011;99:S486–7. doi:10.1016/S0167-8140(11)71421-9.

    Article  Google Scholar 

  23. Heemsbergen WD, Al-Mamgani A, Slot A, et al. Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol. 2014;110:104–9. doi:10.1016/j.radonc.2013.09.026.

    Article  PubMed  Google Scholar 

  24. Henderson DR, Tree AC, van As NJ. Stereotactic body radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol). 2015;27:270–9. doi:10.1016/j.clon.2015.01.011.

    Article  CAS  Google Scholar 

  25. Hoffman KE, Voong KR, Pugh TJ, et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014;88:1074–84. doi:10.1016/j.ijrobp.2014.01.015.

    Article  PubMed  Google Scholar 

  26. Hummel S, Simpson EL, Hemingway P, et al. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1–108. doi:10.3310/hta14470, iii–iv.

    Article  CAS  PubMed  Google Scholar 

  27. Hummel SR, Stevenson MD, Simpson EL, Staffurth J. A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol). 2012;24:e159–67. doi:10.1016/j.clon.2012.09.003.

    Article  CAS  Google Scholar 

  28. Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA. Flat-panel cone-beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:1337–49.

    Article  PubMed  Google Scholar 

  29. James ND, Spears MR, Clarke NW, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer. JAMA Oncol. 2016;2:1–10. doi:10.1001/jamaoncol.2015.4350.

    Google Scholar 

  30. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014;4:240. doi:10.3389/fonc.2014.00240.

    PubMed  PubMed Central  Google Scholar 

  31. Kjær-Kristoffersen F, Ohlhues L, Medin J, Korreman S. RapidArc volumetric modulated therapy planning for prostate cancer patients. Acta Oncol. 2009;48:227–32. doi:10.1080/02841860802266748.

    Article  PubMed  Google Scholar 

  32. Koontz BF, Bossi A, Cozzarini C, et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015;68:683–91. doi:10.1016/j.eururo.2014.08.009.

    Article  PubMed  Google Scholar 

  33. Kotte ANTJ, Hofman P, Lagendijk JJW, et al. Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2007;69:419–25. doi:10.1016/j.ijrobp.2007.03.029.

    Article  PubMed  Google Scholar 

  34. Kuban DA, Nogueras-Gonzalez GM, Hamblin L, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys. 2010;78:S58–9. doi:10.1016/j.ijrobp.2010.07.170.

    Article  Google Scholar 

  35. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74. doi:10.1016/j.ijrobp.2007.06.054.

    Article  PubMed  Google Scholar 

  36. Lawton CA, DeSilvio M, Roach M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646–55. doi:10.1016/j.ijrobp.2007.04.003.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lawton CAF, Michalski J, El-Naqa I, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:383–7. doi:10.1016/j.ijrobp.2008.08.002.

    Article  PubMed  Google Scholar 

  38. Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016. doi:10.1200/JCO.2016.67.0448.

    PubMed Central  Google Scholar 

  39. Ling CC, Burman C, Chui CS, et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys. 1996;35:721–30.

    Article  CAS  PubMed  Google Scholar 

  40. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132–8. doi:10.1200/JCO.2005.06.153.

    Article  PubMed  Google Scholar 

  41. Mohan R, Wang X, Jackson A, et al. The potential and limitations of the inverse radiotherapy technique. Radiother Oncol. 1994;32:232–48.

    Article  CAS  PubMed  Google Scholar 

  42. Mottet N, Bellmunt J, Briers E, et al. members of the EAU – ESTRO – SIOG prostate cancer guidelines panel. EAU – ESTRO – SIOG guidelines on prostate cancer. Edn. Presented at the EAU Annual congress Munich. ISBN 978-90-79754-98-4. Arnhem: EAU Guidelines Office; 2016.

    Google Scholar 

  43. Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69:9–12. doi:10.1016/j.eururo.2015.07.004.

    Article  PubMed  Google Scholar 

  44. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31:3860–8. doi:10.1200/JCO.2013.51.1972.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Pommier P, Chabaud S, Lagrange J-L, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366–73. doi:10.1200/JCO.2006.10.5171.

    Article  PubMed  Google Scholar 

  46. Sale C, Moloney P. Dose comparisons for conformal, IMRT and VMAT prostate plans. J Med Imaging Radiat Oncol. 2011;55:611–21. doi:10.1111/j.1754-9485.2011.02310.x.

    Article  PubMed  Google Scholar 

  47. Scarbrough TJ, Golden NM, Ting JY, et al. Comparison of ultrasound and implanted seed marker prostate localization methods: implications for image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:378–87. doi:10.1016/j.ijrobp.2006.01.008.

    Article  PubMed  Google Scholar 

  48. Sheets N, Goldin GH, Meyer AM, et al. Comparative long-term morbidity of intensity modulated vs. conformal radiation therapy (RT) for prostate cancer: a SEER-Medicare analysis. Int J Radiat Oncol Biol Phys. 2011;81:S43. doi:10.1016/j.ijrobp.2011.06.087.

    Article  Google Scholar 

  49. Silva C, Mateus D, Eiras M, Vieira S. Calypso® 4D localization system: a review. J Radiother Pract. 2014;13:473–83. doi:10.1017/S1460396914000223.

    Article  Google Scholar 

  50. van der Heide UA, Kotte ANTJ, Dehnad H, et al. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer. Radiother Oncol. 2007;82:38–45. doi:10.1016/j.radonc.2006.11.002.

    Article  PubMed  Google Scholar 

  51. Vargas CE, Hartsell WF, Dunn M, et al. Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002. Am J Clin Oncol. 2015; 1. doi: 10.1097/COC.0000000000000241.

  52. Webb S. Optimisation of conformal radiotherapy dose distribution by simulated annealing. Phys Med Biol. 1989;34:1349–70. doi:10.1088/0031-9155/34/10/002.

    Article  CAS  PubMed  Google Scholar 

  53. Wilkins A, Mossop H, Syndikus I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2015;16:1605–16. doi:10.1016/S1470-2045(15)00280-6.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Wolff D, Stieler F, Welzel G, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009;93:226–33. doi:10.1016/j.radonc.2009.08.011.

    Article  PubMed  Google Scholar 

  55. Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys. 2011;81:1271–8. doi:10.1016/j.ijrobp.2010.07.1984.

    Article  PubMed  Google Scholar 

  56. Yirmibeşoğlu Erkal E, Karabey S, Karabey A, et al. Defining the “Hostile Pelvis” for intensity modulated radiation therapy: the impact of anatomic variations in pelvic dimensions on dose delivered to target volumes and organs at risk in patients with high-risk prostate cancer treated with whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:894–903. doi:10.1016/j.ijrobp.2015.03.014.

    Article  PubMed  Google Scholar 

  57. Zaorsky NG, Ohri N, Showalter TN, et al. Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treat Rev. 2013;39:728–36. doi:10.1016/j.ctrv.2013.01.008.

    Article  PubMed  Google Scholar 

  58. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241–9.

    Article  CAS  PubMed  Google Scholar 

  59. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–9. doi:10.1016/j.ijrobp.2007.11.044.

    Article  PubMed  Google Scholar 

  60. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95–09. J Clin Oncol. 2010;28:1106–11. doi:10.1200/JCO.2009.25.8475.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiff University, Velindre Hospital, Whitchurch Cardiff, CF14 2TL, UK

    Malcolm Mason

Authors
  1. Malcolm Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Malcolm Mason .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Hôpital Albert Michallon, Grenoble, France

    Michel Bolla

  2. Department of Urology, University Hospitals Leuven, Leuven, Belgium

    Hendrik van Poppel

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mason, M. (2017). IMRT, Hypofractionated Radiotherapy and Stereotactic Radiotherapy: Technique, Indications, and Results. In: Bolla, M., van Poppel, H. (eds) Management of Prostate Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-42769-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42769-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42768-3

  • Online ISBN: 978-3-319-42769-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation